MY204493A - Ganaxolone for use in treating genetic epileptic disorders - Google Patents
Ganaxolone for use in treating genetic epileptic disordersInfo
- Publication number
- MY204493A MY204493A MYPI2020002311A MYPI2020002311A MY204493A MY 204493 A MY204493 A MY 204493A MY PI2020002311 A MYPI2020002311 A MY PI2020002311A MY PI2020002311 A MYPI2020002311 A MY PI2020002311A MY 204493 A MY204493 A MY 204493A
- Authority
- MY
- Malaysia
- Prior art keywords
- mammal
- ganaxolone
- preferred embodiments
- certain preferred
- neurosteroid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584403P | 2017-11-10 | 2017-11-10 | |
| PCT/US2018/060037 WO2019094724A1 (en) | 2017-11-10 | 2018-11-09 | Ganaxolone for use in treating genetic epileptic disoders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY204493A true MY204493A (en) | 2024-08-30 |
Family
ID=66438123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2020002311A MY204493A (en) | 2017-11-10 | 2018-11-09 | Ganaxolone for use in treating genetic epileptic disorders |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20190160078A1 (enExample) |
| EP (1) | EP3706755A4 (enExample) |
| JP (3) | JP7312169B2 (enExample) |
| KR (1) | KR20200085837A (enExample) |
| CN (1) | CN111565724A (enExample) |
| AU (2) | AU2018364659A1 (enExample) |
| CA (1) | CA3079259A1 (enExample) |
| EA (1) | EA202091144A1 (enExample) |
| MY (1) | MY204493A (enExample) |
| SG (2) | SG10202110563YA (enExample) |
| WO (1) | WO2019094724A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6205362B2 (ja) | 2011-09-08 | 2017-09-27 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| DK2806877T3 (da) | 2012-01-23 | 2019-11-04 | Sage Therapeutics Inc | Neuroaktive steroidformuleringer omfattende et kompleks af allopregnanolon og sulfobutylether beta-cyclodekstrin |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| SMT201800657T1 (it) | 2013-03-13 | 2019-01-11 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| EP2986623B1 (en) | 2013-04-17 | 2018-11-07 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
| SI2986624T1 (sl) | 2013-04-17 | 2020-10-30 | Sage Therapeutics, Inc. | 19-nor nevroaktivni steroidi za metode zdravljenja |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| SI3021852T1 (sl) | 2013-07-19 | 2021-07-30 | Sage Therapeutics, Inc. | Nevroaktivni steroidi, sestavki in uporabe le-teh |
| JP6466942B2 (ja) | 2013-08-23 | 2019-02-06 | セージ セラピューティクス， インコーポレイテッド | 向神経活性ステロイド、組成物、及びその使用 |
| ES2970222T3 (es) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| EP4527461A3 (en) | 2014-10-16 | 2025-06-25 | Sage Therapeutics, Inc. | A compound, compositions thereof and this compound for use in methods of treating cns disorders |
| RS60642B1 (sr) | 2014-10-16 | 2020-09-30 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns-a |
| SMT202000276T1 (it) | 2014-11-27 | 2020-07-08 | Sage Therapeutics Inc | Composizioni e metodi per trattare disturbi del snc |
| SMT202100113T1 (it) | 2015-01-26 | 2021-05-07 | Sage Therapeutics Inc | Composizioni e metodi per trattare disturbi del snc |
| JP6875996B2 (ja) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
| SG10202002655VA (en) | 2015-07-06 | 2020-05-28 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| SMT202100226T1 (it) | 2015-07-06 | 2021-05-07 | Sage Therapeutics Inc | Ossisteroli e metodi di uso degli stessi |
| EP3319610A4 (en) | 2015-07-06 | 2019-03-06 | Sage Therapeutics, Inc. | OXYSTEROLS AND METHOD OF USE THEREOF |
| WO2017156103A1 (en) | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| PL3436022T3 (pl) | 2016-04-01 | 2022-08-08 | Sage Therapeutics, Inc. | Oksysterole i sposoby ich stosowania |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| HUE055263T2 (hu) | 2016-07-07 | 2021-11-29 | Sage Therapeutics Inc | 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére |
| IL264129B2 (en) | 2016-07-11 | 2024-05-01 | Sage Therapeutics Inc | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| NZ790187A (en) | 2016-07-11 | 2025-08-29 | Sage Therapeutics Inc | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| TWI854445B (zh) | 2016-08-23 | 2024-09-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| ES2935057T3 (es) | 2016-09-30 | 2023-03-01 | Sage Therapeutics Inc | C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA |
| CN119350419A (zh) | 2016-10-18 | 2025-01-24 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| ES3038660T3 (en) | 2016-10-18 | 2025-10-14 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| JP2022514510A (ja) * | 2018-12-14 | 2022-02-14 | プラクシス プレシジョン メディスンズ，インコーポレイテッド | うつ病の治療方法 |
| WO2020135454A1 (zh) * | 2018-12-26 | 2020-07-02 | 张家口华健致远生物科技有限公司 | 一类类固醇化合物及其用途 |
| SG11202112391UA (en) | 2019-05-31 | 2021-12-30 | Sage Therapeutics Inc | Neuroactive steroids and compositions thereof |
| JP2022540253A (ja) | 2019-07-11 | 2022-09-14 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｔ型カルシウムチャネル調節因子の製剤およびその使用方法 |
| IL291818A (en) * | 2019-10-02 | 2022-06-01 | Praxis Prec Medicines Inc | Combinations of gaba-a receptor positive allosteric modulators and nmda antagonists, nmda negative allosteric modulators or nmda partial agonists |
| AU2020395254A1 (en) | 2019-12-06 | 2022-06-02 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating tuberous sclerosis complex |
| CN115776894A (zh) * | 2020-04-29 | 2023-03-10 | 普拉西斯精密医药公司 | T型钙通道调节剂的使用方法 |
| CN114304068B (zh) * | 2020-09-30 | 2025-07-18 | 中国科学院脑科学与智能技术卓越创新中心 | 癫痫动物模型的制备及其应用 |
| WO2022125408A1 (en) * | 2020-12-07 | 2022-06-16 | Marinus Pharmaceuticals, Inc | Use of ganaxolone in treating an epilepsy disorder |
| US20230321116A1 (en) * | 2022-02-16 | 2023-10-12 | Lipocine Inc. | 3Alpha-OH-5Beta-Pregnan-20-One Compositions and Methods for Treating Central Nervous System Disorders |
| EP4412619A4 (en) | 2021-10-04 | 2025-11-12 | Marinus Pharmaceuticals Inc | GANAXOLONE FOR THE TREATMENT OF BOURNEVILLE'S TUBEROUS SCLEROSIS AND EPILEPTIC DISORDERS |
| WO2023060067A1 (en) * | 2021-10-04 | 2023-04-13 | Marinus Pharmaceuticals, Inc. | Amorphous solid dispersion ganaxolone formulation |
| CN119604281A (zh) * | 2022-06-02 | 2025-03-11 | 来普卡公司 | 治疗癫痫的方法和组合物 |
| WO2024257008A1 (en) * | 2023-06-13 | 2024-12-19 | Biostrike Unipessoal Lda | Compounds for diagnosing and treating epilepsy syndromes, methods and uses thereof |
| WO2025248486A1 (en) * | 2024-05-29 | 2025-12-04 | Biostrike Unipessoal Lda | Compounds for preventing sudden death in epilepsy (sudep), methods and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5556847A (en) * | 1994-10-27 | 1996-09-17 | Duquesne University Of The Holy Ghost | Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors |
| US5888996A (en) * | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| DK2806877T3 (da) * | 2012-01-23 | 2019-11-04 | Sage Therapeutics Inc | Neuroaktive steroidformuleringer omfattende et kompleks af allopregnanolon og sulfobutylether beta-cyclodekstrin |
| CA2882708A1 (en) * | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| US9629853B2 (en) * | 2014-05-21 | 2017-04-25 | Wisconsin Alumni Research Foundation | Uses of ganaxolone |
| CA3254865A1 (en) * | 2015-02-06 | 2025-05-28 | Marinus Pharmaceuticals, Inc. | Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders |
| MX2018004376A (es) * | 2015-10-16 | 2018-08-01 | Marinus Pharmaceuticals Inc | Formulaciones inyectables de neuroesteroides que contienen nanoparticulas. |
| WO2017156103A1 (en) * | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| KR102518846B1 (ko) * | 2016-08-11 | 2023-04-05 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
| CA3060255A1 (en) * | 2017-04-18 | 2018-10-25 | Marinus Pharmaceuticals, Inc | Sustained release injectable neurosteroid formulations |
-
2018
- 2018-11-09 SG SG10202110563YA patent/SG10202110563YA/en unknown
- 2018-11-09 WO PCT/US2018/060037 patent/WO2019094724A1/en not_active Ceased
- 2018-11-09 EA EA202091144A patent/EA202091144A1/ru unknown
- 2018-11-09 MY MYPI2020002311A patent/MY204493A/en unknown
- 2018-11-09 JP JP2020526304A patent/JP7312169B2/ja active Active
- 2018-11-09 AU AU2018364659A patent/AU2018364659A1/en not_active Abandoned
- 2018-11-09 CA CA3079259A patent/CA3079259A1/en active Pending
- 2018-11-09 EP EP18876989.7A patent/EP3706755A4/en active Pending
- 2018-11-09 CN CN201880085880.3A patent/CN111565724A/zh active Pending
- 2018-11-09 US US16/185,677 patent/US20190160078A1/en not_active Abandoned
- 2018-11-09 KR KR1020207016409A patent/KR20200085837A/ko not_active Ceased
- 2018-11-09 SG SG11202004329TA patent/SG11202004329TA/en unknown
-
2022
- 2022-03-24 US US17/703,331 patent/US20220249515A1/en not_active Abandoned
-
2023
- 2023-07-07 JP JP2023112339A patent/JP2023153783A/ja active Pending
-
2024
- 2024-03-21 US US18/612,277 patent/US20250082651A1/en active Pending
- 2024-10-15 AU AU2024227357A patent/AU2024227357A1/en not_active Abandoned
-
2025
- 2025-04-16 JP JP2025067224A patent/JP2025118661A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200085837A (ko) | 2020-07-15 |
| WO2019094724A1 (en) | 2019-05-16 |
| JP7312169B2 (ja) | 2023-07-20 |
| AU2018364659A1 (en) | 2020-05-28 |
| SG11202004329TA (en) | 2020-06-29 |
| EP3706755A4 (en) | 2021-11-10 |
| WO2019094724A8 (en) | 2022-10-06 |
| JP2021502403A (ja) | 2021-01-28 |
| US20220249515A1 (en) | 2022-08-11 |
| CN111565724A (zh) | 2020-08-21 |
| EP3706755A1 (en) | 2020-09-16 |
| JP2025118661A (ja) | 2025-08-13 |
| US20190160078A1 (en) | 2019-05-30 |
| EA202091144A1 (ru) | 2020-09-16 |
| CA3079259A1 (en) | 2019-05-16 |
| JP2023153783A (ja) | 2023-10-18 |
| SG10202110563YA (en) | 2021-11-29 |
| AU2024227357A1 (en) | 2024-10-31 |
| US20250082651A1 (en) | 2025-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY204493A (en) | Ganaxolone for use in treating genetic epileptic disorders | |
| PH12019501120A1 (en) | Methods of treating inflammatory conditions | |
| WO2019094642A8 (en) | T cell manufacturing compositions and methods | |
| MX2017005875A (es) | Metodos para tratar enfermedades oculares. | |
| MX2011007854A (es) | Metodos para tratar infartos agudos al miocardio y trastornos relacionados. | |
| HK1246712A1 (zh) | 神经刺激治疗疾病及病症 | |
| NZ751690A (en) | Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves | |
| MX2016005159A (es) | Metodos de diagnostico y tratamiento de trastornos eosinofilicos. | |
| MY191040A (en) | Therapy involving antibodies against claudin 18.2 for treatment of cancer | |
| EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
| PH12020500570A1 (en) | Alpha-synuclein antisense oligonucleotides and uses thereof | |
| MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| MX2010003548A (es) | Metodos para el tratamiento de padecimientos neurologicos autoinmunes con ciclofosfamida. | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| WO2006014159A3 (en) | Methods of using regenerative cells in the treatment of musculoskeletal disorders | |
| MX2019015741A (es) | Tratamiento con plasminogeno de afecciones asociadas a la sobreexpresion de pai-1. | |
| EA201790563A1 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| WO2014184576A3 (en) | Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain | |
| MY187167A (en) | Medical treatments based on anamorelin | |
| EP4285993A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
| MX2021011269A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina. | |
| SA520412423B1 (ar) | أوليجونيوكليوتيدات مضادة للحس تستهدف ألفا- سينيوكلين واستخداماتها | |
| MX2020003243A (es) | Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada. | |
| WO2019043649A3 (en) | ANGIO -3 FOR THE TREATMENT OF RETINAL ANGIOGENIC DISEASES | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) |